The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes of patients with mNSGCTs with and without teratoma in the primary tumor: An international retrospective study.
 
Manuel Pedregal
No Relationships to Disclose
 
Begoña Valderrama
Honoraria - AAA HealthCare; Almirall; Astellas Pharma; AstraZeneca Spain; Bayer; Bristol-Myers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer; Recordati
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Merck; MSD Oncology; Pfizer; Roche
 
Rafael Morales-Barrera
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck/Pfizer; MSD; Sanofi
Speakers' Bureau - Astellas Pharma; Merck/Pfizer; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Merck; MSD; Pfizer; Roche/Genentech; Sanofi
 
Isabel Miras
No Relationships to Disclose
 
David Marmolejo Castañeda
No Relationships to Disclose
 
Nora Sobrevilla
No Relationships to Disclose
 
Maria Bourlon
Leadership - BMS
Honoraria - BMS; Tecnofarma; Tecnofarma
Consulting or Advisory Role - Asofarma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Gilead Sciences; Gilead Sciences; Janssen Oncology; Merck; MSD; MSD Oncology; Novartis; Novartis; Pfizer
Speakers' Bureau - Asofarma; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Ipsen; Janssen Oncology; Medicamenta; Merck; MSD Oncology; Pfizer; Tecnofarma
Research Funding - Janssen Oncology (Inst); Pfizer
Expert Testimony - Asofarma
Travel, Accommodations, Expenses - Asofarma; Bristol-Myers Squibb (Mexico); Janssen-Cilag; MSD Oncology; Pfizer
Other Relationship - Sanofi
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Ellipses Pharma; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Praful Ravi
Consulting or Advisory Role - Bayer
Research Funding - Bayer (Inst); Lantheus Medical Imaging (Inst); Lilly (Inst); Novartis (Inst); Telix Pharmaceuticals (Inst)
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Cadence Pharma; CellCentric; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination